Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Arterial events in cancer patients treated with apixaban for venous thrombosis.
Larsen TL, Svalastoga M, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA. Larsen TL, et al. Among authors: froen h. Thromb Res. 2023 Aug;228:128-133. doi: 10.1016/j.thromres.2023.05.017. Epub 2023 May 25. Thromb Res. 2023. PMID: 37327527
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.
Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Osvik Velle E, Skuterud Wik H, Ghanima W, Sandset PM, Dahm AEA. Larsen TL, et al. Among authors: froen h. J Thromb Haemost. 2022 May;20(5):1166-1181. doi: 10.1111/jth.15666. Epub 2022 Feb 20. J Thromb Haemost. 2022. PMID: 35114046 Free article. Clinical Trial.
"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply.
Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA. Larsen TL, et al. Among authors: froen h. J Thromb Haemost. 2022 Aug;20(8):1937-1939. doi: 10.1111/jth.15774. J Thromb Haemost. 2022. PMID: 35859282 Free article. No abstract available.
Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Berentsen S, et al. Among authors: froen h. Blood. 2020 Jul 23;136(4):480-488. doi: 10.1182/blood.2020005674. Blood. 2020. PMID: 32374875 Free article. Clinical Trial.
Norske leger varsler om klima.
Frøen H. Frøen H. Tidsskr Nor Laegeforen. 2024 Aug 29;144(10). doi: 10.4045/tidsskr.24.0366. Print 2024 Sep 10. Tidsskr Nor Laegeforen. 2024. PMID: 39254018 Free article. Norwegian. No abstract available.
Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
Nyquist OE, Dalgaard J, Spetalen S, Torkildsen S, Frøen H, Galteland E, Klungsøyr O, Bergrem A, Vo C, Sørbø H, Eiken B, Lerdal H, Solvang AK, Jensvoll H, Pandzic T, Baliakas P, Dybedal I. Nyquist OE, et al. Among authors: froen h. Br J Haematol. 2024 Feb;204(2):724-729. doi: 10.1111/bjh.19226. Epub 2023 Nov 28. Br J Haematol. 2024. PMID: 38016923 No abstract available.
15 results